<DOC>
	<DOCNO>NCT03048448</DOCNO>
	<brief_summary>This study characterize pharmacokinetics ( PK ) QAW039 single oral dose QAW039 patient hepatic impairment compare healthy match control subject .</brief_summary>
	<brief_title>Pharmacokinetics Fevipiprant ( QAW039 ) Patients With Hepatic Impairment Compared Matched Healthy Subjects</brief_title>
	<detailed_description>The purpose study determine pharmacokinetic profile Fevipiprant different patient hepatic impairment compare healthy match volunteer extent would require adjustment dosage . Data study use guide enrollment criterion future clinical trial support regulatory submission label information .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Indoleacetic Acids</mesh_term>
	<criteria>All subject Weight least 50 kg 120 kg body mass index range 18.036.0 kg/m2 Patients hepatic impairment Moderate hepatic impairment ( Group 1 ) : ChildPugh Class B ( 79 point ) , Severe hepatic impairment ( Group 2 ) : ChildPugh Class C ( 1015 point Mild hepatic impairment ( Group 4 ) : ChildPugh Class A ( 56 point ) Healthy subject Match age ( ±5 year ) , gender , smoke status , weight ( ± 15 % ) individual patient . In good health determine past medical history , physical examination , electrocardiogram , laboratory test urinalysis screen . All subject History hypersensitivity and/or idiosyncracies QAW039 drug similar class ( CRTh2 antagonists ) . Use comedications may impact QAW039 exposure broad range UGT inhibitor strong inhibitor OAT3 , OATP1B3 , Pgp , include limited probenecid , ritonavir , valproic acid , rifampin Surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize subject case participation study . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Pregnant nursing ( lactate ) woman . Women childbearing potential Patients hepatic impairment Hepatic impairment due nonliver disease ( e.g. , right heart failure ) Current symptom history encephalopathy Grade III IV within past 6 month Primary biliary liver cirrhosis biliary obstruction Emergency room visit hospitalization due liver disease within precede 3 month . Severe complication liver disease within precede 3 month . Healthy subject Liver disease liver injury indicate abnormal liver function test . Any single parameter ALT , AST , γGT , alkaline phosphatase serum bilirubin must exceed 1.5 x upper limit normal ( ULN ) Any elevation ULN one parameter ALT , AST , γ GT , alkaline phosphatase serum bilirubin exclude subject participation study A positive Hepatitis B surface antigen Hepatitis C test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatic impairment ,</keyword>
	<keyword>Fevipiprant ,</keyword>
	<keyword>adult ,</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>